Estimating the Optimal Perioperative Chemotherapy Utilization Rate for Muscle-invasive Bladder Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Sep 1

PMID 31472011

Citations 3

Authors

Safiya Karim

William J Mackillop

Kelly Brennan

Yingwei Peng

D Robert Siemens

Monika K Krzyzanowska

Christopher M Booth

Affiliations

Soon will be listed here.

Abstract

Background: Identifying optimal chemotherapy (CT) utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle-invasive bladder cancer (MIBC).

Methods: The Ontario Cancer Registry and linked treated records were used to identify neoadjuvant and adjuvant CT rates among patients with MIBC during 2004-2013. Monte Carlo simulation was used to estimate the proportion of observed rate variation that could be due to chance alone. The criterion-based benchmarking approach was used to explore whether social and health-system factors were associated with CT rates. We also used the "pared-mean" approach to identify a benchmark population of hospitals with the highest treatment rates. Hospital CT rates were adjusted for case mix and simulated using a multi-level multivariable model and a parametric bootstrapping approach.

Results: The study population included 2581 patients; perioperative CT was delivered to 31% (798/2581). Multivariate analysis showed that treatment was strongly associated with patient socioeconomic status and hospital teaching status. The benchmark rate was 36%. Unadjusted CT rates were significantly different across hospitals (range 0%-52%, P < .001). The unadjusted benchmark perioperative CT rate was 45% (95% CI 40%-50%); utilization rate in nonbenchmark hospitals was 28% (95% CI 26%-30%). When using simulated CT rates adjusted for case mix, the benchmark CT rate was 41% (95% CI 35%-47%) and the nonbenchmark hospital CT rate was 30% (95% CI 28%-32%). The simulation analysis suggested that the observed component of variation (38%) was outside the 95% CI (22%-28%) of what could be expected due to chance alone.

Conclusions: There is significant systematic variation in perioperative CT rates for MIBC across hospitals in routine practice. The benchmark perioperative CT rate for MIBC is 36%-41%.

Citing Articles

Outcomes of radical cystectomy in a resource-limited setting: a pilot study.

Taha S, Abdallah A, Osman Y, Taha M, Elhassan M, Ahmed M BMC Urol. 2025; 25(1):31.

PMID: 39966820 PMC: 11834187. DOI: 10.1186/s12894-025-01713-x.

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

van Hoogstraten L, Man C, Witjes J, Meijer R, Mulder S, Smilde T World J Urol. 2023; 41(7):1837-1845.

PMID: 37258902 PMC: 10231297. DOI: 10.1007/s00345-023-04443-7.

Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.

Black P, Alimohamed N, Kassouf W, Gore J, McCoy K, Nelson B Can Urol Assoc J. 2022; 16(6):E307-E314.

PMID: 35623004 PMC: 9245967. DOI: 10.5489/cuaj.7810.

Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer.

Karim S, Mackillop W, Brennan K, Peng Y, Siemens D, Krzyzanowska M Cancer Med. 2019; 8(14):6258-6271.

PMID: 31472011 PMC: 6797575. DOI: 10.1002/cam4.2449.

References

Booth C, Siemens D, Li G, Peng Y, Tannock I, Kong W . Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 2014; 120(11):1630-8. DOI: 10.1002/cncr.28510. View

Booth C, Mackillop W . Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA. 2008; 300(18):2177-9. DOI: 10.1001/jama.300.18.2177. View

Ruggeri E, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F . Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer. 2006; 106(4):783-8. DOI: 10.1002/cncr.21676. View

Barbera L, Zhang-Salomons J, Huang J, Tyldesley S, Mackillop W . Defining the need for radiotherapy for lung cancer in the general population: a criterion-based, benchmarking approach. Med Care. 2003; 41(9):1074-85. DOI: 10.1097/01.MLR.0000083742.29541.BC. View

David K, Milowsky M, Ritchey J, Carroll P, Nanus D . Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178(2):451-4. DOI: 10.1016/j.juro.2007.03.101. View

Hermans T, Fransen van de Putte E, Horenblas S, Lemmens V, Aben K, van der Heijden M . Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands. Eur J Cancer. 2015; 54:18-26. DOI: 10.1016/j.ejca.2015.11.006. View

Mackillop W, Groome P, Zhou Y, Feldman-Stewart D, Paszat L, Dixon P . Does a centralized radiotherapy system provide adequate access to care?. J Clin Oncol. 1997; 15(3):1261-71. DOI: 10.1200/JCO.1997.15.3.1261. View

Karim S, Mackillop W, Brennan K, Peng Y, Siemens D, Krzyzanowska M . Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. Cancer Med. 2019; 8(14):6258-6271. PMC: 6797575. DOI: 10.1002/cam4.2449. View

Mackillop W, Zhang-Salomons J, Groome P, Paszat L, Holowaty E . Socioeconomic status and cancer survival in Ontario. J Clin Oncol. 1997; 15(4):1680-9. DOI: 10.1200/JCO.1997.15.4.1680. View

10.

Porter M, Kerrigan M, Donato B, Ramsey S . Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2009; 29(3):252-8. DOI: 10.1016/j.urolonc.2009.03.021. View

11.

Reardon Z, Patel S, Zaid H, Stimson C, Resnick M, Keegan K . Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2014; 67(1):165-170. PMC: 4469385. DOI: 10.1016/j.eururo.2014.01.009. View

12.

Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar M . International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16):2171-7. PMC: 3107740. DOI: 10.1200/JCO.2010.32.3139. View

13.

Weissman N, Allison J, Kiefe C, Farmer R, Weaver M, Williams O . Achievable benchmarks of care: the ABCs of benchmarking. J Eval Clin Pract. 1999; 5(3):269-81. DOI: 10.1046/j.1365-2753.1999.00203.x. View

14.

Kerba M, Miao Q, Zhang-Salomons J, Mackillop W . Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol (R Coll Radiol). 2010; 22(10):801-9. DOI: 10.1016/j.clon.2010.07.006. View

15.

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

16.

Mackillop W, Kong W . Estimating the Need for Palliative Radiation Therapy: A Benchmarking Approach. Int J Radiat Oncol Biol Phys. 2015; 94(1):51-59. DOI: 10.1016/j.ijrobp.2015.09.045. View

17.

Robles S, Marrett L, Clarke E, Risch H . An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988; 41(5):495-501. DOI: 10.1016/0895-4356(88)90052-2. View

18.

Booth C, Karim S, Brennan K, Siemens D, Peng Y, Mackillop W . Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?. Urol Oncol. 2017; 36(3):89.e13-89.e20. DOI: 10.1016/j.urolonc.2017.11.015. View

19.

Kong W, Jarvis C, Mackillop W . Estimating the need for palliative radiotherapy for brain metastasis: a benchmarking approach. Clin Oncol (R Coll Radiol). 2014; 27(2):83-91. DOI: 10.1016/j.clon.2014.11.001. View

20.

. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48(2):189-199. DOI: 10.1016/j.eururo.2005.04.005. View